Interview with Melvin Oscar D'souza, Managing Director, Novo Nordisk India…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
Address: Novo Nordisk India Limited, Plot No.32, 47-50, EPIP Area, Whiltefield, Bangalore – 560 066, India
Tel: +91 80 4030 3200
Web: http://www.novonordisk.co.in/documents/home_page/document/index.asp
Novo Nordisk India story
The genesis of Novo Nordisk India goes back to 1990 when a liaison office of Novo Nordisk A/S, was set up in Mumbai. Prior to this Novo Nordisk A/S products were marketed in India through various other companies. Even then, Novo Nordisk was involved in creating awareness in diabetes care with the help of healthcare professionals in India.
On April 1, 1994, Novo Nordisk (I) Pvt. Ltd. was set up with its headquarters in Bangalore with 26 employees. It has now been rechristened as Novo Nordisk India Private Limited.
In 1998, recognising the intense need to provide awareness and education in healthcare in India, the Novo Nordisk Education Foundation (NNEF) was founded. NNEF is a non-profit organisation, with a mission of ‘Enhancing healthcare through awareness and education’.
Novo Nordisk India’s portfolio of products and services deals with therapy areas in Diabetes, Human Growth Hormone and Haemostasis Management.
Novo Nordisk is synonymous with diabetes care inIndia . Novo Nordisk has introduced products and services hitherto not seen in the area of diabetes care in the country.
Over the last decade Novo Nordisk has been able to ensure that there is a marked improvement in the way people with diabetes live and work.
As part of our efforts to be at the forefront of bringing information to people with diabetes in India, we have attempted to highlight various aspects of diabetes which you would like to know about.
As part of our activities, we have always endeavoured to stay in touch with persons with diabetes as well as the medical fraternity.
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
Novo Nordisk seems somewhat of an exception to the MNCs that recently entered India, as it already set up its HQ in Bangalore in 1994. How do you explain this…
As managing director of India’s fifth largest pharmaceutical company, Zydus Cadila’s Sharvil Patel shares his insights on his impressive internationalization strategy with a special focus on the US where Zydus…
A successful commercial leader, Annaswamy Vaidheesh, president of OPPI, VP South Asia and managing director at GSK India, talks about the tremendous work that the local affiliate is doing in…
A strong supporter of public-private partnerships, MSD’s managing director in India, Vivek Kamath, explains how the company’s collaborative approach is the key to enhancing their reputation, improving patient outcomes and…
Ashok Battacharya, executive director of the Indian affiliate of Takeda Pharmaceuticals, with 38 years experience in global Ppharmaceutical MNCs, discusses the top-notch reputation that Takeda has among physicians and patients…
Think global, act local! This is the Novartis business approach in India. A great believer in stakeholder collaboration, Jawed Zia, country president of Novartis India, explains how co-marketing deals with…
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
Alexandre Williams, founder and managing director of Athena, an international company with an Indian manufacturing basis specialized in life cycle products, provides insights into some key trends shaping India’s pharmaceutical…
As the founder and chairman of Alves Group, a key Indian player in medical devices with an extensive portfolio, Randolph Alves shares the challenges India needs to overcome to remain…
Dharmesh Shah, managing director of BDR Pharmaceuticals, a company with a strong expertise in oncology, intensive care, and other therapeutic areas, provides us with an insightful overview of the main…
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’…
See our Cookie Privacy Policy Here
